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Coronavirus disease (COVID-19) is an infectious 
disease caused by SARS-CoV-2 (Severe acute 
respiratory syndrome coronavirus 2)1. World Health 
Organization (WHO) declared it a Public Health 
Emergency of International Concern on 30th January 
2020 and a pandemic on 11th March 2020 after 
assessing its global spread2,3. A total of 7,039,918 
cases have been confirmed with COVID-19 disease 
and 404,396 reported deaths globally with the highest 
number of cases in the USA, Brazil, Russian 
Federation, UK, India, Spain, Italy, Peru, Germany, 
Iran, Turkey, and France. A total of 266,598 cases 
have been confirmed in India with 7,466 reported 
deaths as of 9th June 2020(ref.4). Various guidelines 
have been developed for its prevention and control 
but the number of confirmed cases as well as death 
tolls is going-up aggressively day by day5. 
As of now, there is no specific vaccine or treatment 
option available to prevent or cure COVID-19. Lots 
of efforts by the conventional system of medicine are 
going on to find out effective management of this 
deadly disease, still, no significant solution has been 
appeared even in the countries having the best public 
healthcare systems6,7. Alongside, traditional medicine 
experts are also working diligently to play their part in 
the prevention as well as treatment of COVID-19. 
Currently, several clinical trials are going-on 
including both western and traditional medicines and 
it has been observed that traditional medicines are 
found effective in alleviating the symptoms of 
COVID-19(ref.8). 
India has a well-established, holistic, and scientific 
system of traditional medicine namely Ayurveda, 
which often gets criticized for lack of scientific 
research data to validate its relevance and reliability 
in the present-day healthcare scenario. Although 
research studies have been conducted to generate 
scientific evidence regarding the efficacy and safety 
of Ayurvedic interventions, however, lack of full-
fledged support and discretion to create a conducive 
innate research environment without compromising 
its fundamental principles has been a major hindrance 
in tapping its true potential. 
In this scenario, where conventional medicine is 
still not able to find any cure to this pandemic disease 
and traditional and complementary medicines are not 
having any alternative to the tertiary healthcare 
services for terminally ill patients, an integrated 
approach including all medicine systems may give 
promising results in COVID-19 management. This 
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type of medical pluralism with all the rationale is 
required to apply in a controlled environment along 
with conventional approaches and guidelines provided 
by global health agencies. 
The present paper is an attempt to explore the 
potential of Ayurveda in the prevention and 
management of COVID-19 as a standalone system or 
integrated with the western system of medicine with 
pivotal evidence from quintessential classical 
Ayurveda texts of time immemorial and contemporary 
published literature. It is also aimed to make the 
policy-makers and healthcare stakeholders of the 
country appreciate this wealth of traditional scientific 
knowledge and give due recognition by incorporating 
its management principles in the prophylaxis and 
treatment of COVID-19 as per the requirement. 
 
Materials and Methods 
All the relevant sources like Ayurvedic texts with 
their commentaries, Ayurvedic Pharmacopoeia and 
Formulary of India, electronic databases (PubMed, 
Google Scholar, etc.) and websites of government 
health agencies, etc. were searched thoroughly to 
collect the relevant material by using the keywords – 
COVID-19, WHO, CDC, traditional, Chinese 
medicine, Ayurveda, immunity, immunomodulator, 





In December 2019, it was observed that clusters of 
pneumonia cases are occurring in China with 
unknown etiology. The disease was caused by an 
unknown virus initially named as Novel Coronavirus 
(nCoV). Later on, WHO named this virus as Severe 
Acute Respiratory Syndrome coronavirus 2 (SARS-
CoV-2) and disease as Coronavirus disease (COVID-
19) on 11th February 2020. Coronaviruses are a large 
family of viruses that infect animals as well as 
humans. Primary observation determined that SARS-
CoV-2 spreads through small droplets of saliva or 
discharge from the nose or mouth of an infected 
person when he/she coughs or sneezes. Another mode 
of transmission is from infected hands and surfaces 
i.e. when these droplets land on objects and surfaces 
other people may get infected by touching these 
objects or surfaces and then touching their eyes,  
nose, or mouth. Its incubation period ranges from 1 to 
14 days, most commonly around 5 days9. 
These viruses can cause manifestations of the 
respiratory or gastrointestinal system. The common 
signs and symptoms are fever, cough, and shortness 
of breath in mild cases. In more severe cases, the 
infection can cause pneumonia, severe acute 
respiratory syndrome, renal failure, and sometimes 
death. Some patients may experience nasal 
congestion, runny nose, sore throat, aches, and pains 
or diarrhea. Older persons and persons with pre-
existing medical conditions (such as high blood 
pressure, heart disease, lung disease, diabetes 
mellitus, or patients on cancer medication) appear to 
develop serious illness more often than others9. 
The confirmation of COVID-19 disease is based on 
the detection of a unique sequence of virus RNA by a 
nucleic acid amplification test (NAAT) such as real-
time reverse transcription-polymerase chain reaction 
(rRT-PCR) with confirmation by nucleic acid 
sequencing when necessary10. 
Clinical classification of COVID-19 cases as per 
the diagnosis and treatment protocol for Novel 
Coronavirus Pneumonia (Trial Version 7) released by 
the National Health Commission and State 
Administration of Traditional Chinese Medicine on 
3rd March 2020 is shown in Table 1(ref. 11). 
As of now, there is no specific treatment or vaccine 
of COVID-19, however, many ongoing clinical trials 
are evaluating potential treatments. Considering its 
contagiousness, the best method, especially in the 
absence of treatment, is being well informed about the 
disease, its causes, and spreads6. Alongside this, one 
has to strictly follow the preventive measures e.g. 
Respiratory etiquettes, good sanitizing practices, and 
social distancing. The exact mortality rate of the 
disease is also yet unknown; however, it is observed 
that it is having varied fatality rates in different 
countries. Countries like France, Italy and Spain  
with the most efficient healthcare systems (1, 2, and 
7th ranks respectively in WHO Health System 
Performance Ranking-2019)7 are among the countries 
having most COVID-19 positive cases. In this 
scenario, where the countries with efficient healthcare 
systems are finding it difficult to control its spread, 
another best way after prevention is the integration of 
conventional measures with other traditional and 
complementary systems of medicine for prophylaxis 
and initial-stage management. 
 
Ayurvedic concept of infectious diseases 
Ayurveda is probably the world’s first medical 
science describing the concept of contagious or 




communicable diseases under the heading ‘Aupasargika 
Roga’. Diseases like Kushtha (Dermatological 
conditions of contagious nature), Jvara (Fevers of 
infectious origin), Shosha (Pulmonary tuberculosis), 
Netrabhishyanda (Infective conjunctivitis), Shitalika 
(Smallpox), Masurika (Chickenpox), etc. may spread 
from one person to another through various modes of 
exposures i.e. Gatra-samsparsha (Direct contact with an 
infected person or his infective body fluids), Nih-shvasa 
(Inhalation of infective droplets), Saha-bhojana 
(Ingestion of infective organisms when eating together), 
Saha-shaiyya (Sleeping and/or lying together with an 
infected person), Saha-asana (Sitting together with an 
infected person) and Vastra-malya-anulepana (Use of 
contaminated articles)12. Sexual contact with an infected 
person has also been mentioned in the etiology of 
diseases like Upadamsha (Sexually transmitted disease 
causing inflammation of male genitals) and Phiranga 
(Syphilis)13,14. 
The concept of epidemics or pandemics is also well 
described in Ayurveda under the heading of 
‘Janapadodhvamsa’ (Societal collapse), where it has 
been clearly mentioned that vitiation of factors 
common to all inhabitants of a particular region i.e. 
Vayu (Air), Jala (Water), Desha (Land) and Kala 
(Season) may lead to the simultaneous manifestation 
of diseases with similar symptoms leading to the 
societal collapse15. The given examples of epidemic 
or pandemic diseases in Ayurveda include 
Pratishyaya (Coryza), Kasa (Cough), and Shvasa 
(Dyspnea) etc.16. 
Pragyaparadha (Imprudent conduct and unjust 
actions of humans) e.g. Interference with the bio-
ecology, pollution, and depletion of natural resources, 
etc., have been considered the main reason for the 
vitiation of these common factors17. 
Moreover, etiology of Agantuja Vyadhi described 
in Ayurveda includes external factors like Bhuta 
(Micro-organisms), Vayu (Air), Abhighata (Trauma), 
Visha (Poison) etc18. These factors exhibit mild 
symptoms initially but the full-blown disease appears 
only after the vitiation of other host factors i.e. Dosha, 
Dhatu which are responsible for further pathogenesis 
and progression of the disease19. 
 
Table 1 — Clinical classification of COVID-19 cases 
S. No. Clinical classification Criteria (Signs & Symptoms) 
1. Mild cases  Mild symptoms. 
 No signs of pneumonia on imaging. 
2. Moderate cases  Fever and respiratory symptoms. 
 Radiological findings of pneumonia. 
3. Severe cases Adult cases (meeting any of the following criteria): 
 Respiratory distress (Respiratory Rate ≥ 30 Breaths/Min); 
 Oxygen saturation ≤ 93% at rest; 
 Arterial partial pressure of oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤ 
300 mmHg (l mmHg = 0.133 kPa)#; 
 Cases with chest imaging that shows obvious lesion progression within 24-48 
hours > 50% shall be managed as severe cases. 
Child cases (meeting any of the following criteria): 
 Tachypnea (Independent of fever and crying) – 
 Respiratory Rate ≥ 60 Breaths/Min for infants aged < 2 months; 
 Respiratory Rate ≥ 50 Breaths/Min for infants aged 2-12 months; 
 Respiratory Rate ≥ 40 Breaths/Min for children aged 1-5 years,  
 Respiratory Rate ≥ 30 Breaths/Min for children > 5 years 
 Oxygen saturation ≤ 92% on finger pulse oximeter taken at rest;  
 Labored breathing, cyanosis, and intermittent apnea; 
 Lethargy and convulsion; 
 Difficulty feeding and signs of dehydration. 
4. Critical cases  
 
Cases meeting any of the following criteria:  
 Respiratory failure and requiring mechanical ventilation; 
 Shock; 
 With other organ failure that requires ICU care. 
#In areas at altitude of over 1000 meters above the sea-level, PaO2/FiO2 shall be corrected by the formula : PaO2/FiO2 x (Atmospheric 
pressure in mmHg/760) 
 




Ayurvedic concept of immunity and Rasayana 
(Rejuvenation) 
In Ayurveda, the concept of immunity is described 
under multiple headings i.e., Vyadhikshamatva and 
Bala. Vyadhikshamatva is the power of the body to 
fight with a disease by either way20  
1. Vyadhi-Bala-Virodhitvam – The resisting power 
of the body to restrain or withstand the strength or 
severity or progression of the disease. 
2. Vyadhi-Utpada-Pratibandhakatvam – The 
resisting power of the body to prevent the 
manifestation of the disease. 
Bala is said to be of three types which can be 
correlated with different types of immunity i.e.21 – 
1. Sahaja Bala – Natural or innate immunity. 
2. Kalaja Bala – Acquired immunity which depends 
upon the seasons and age of the individual. 
3. Yuktikriti Bala – Acquired immunity which is 
achieved by rational use of Ahara (Diet), Cheshta 
(Daily activities e.g. Exercise, etc.). 
Rasayana in Ayurveda is defined as a measure or 
method used to obtain the optimal level of Dhatu 
(Different structural components of the body)22. 
Rasayana drugs or formulations have multiple 
pharmacological effects on various body systems. Free-
radical scavenging property is the most studied activity 
of Rasayana followed by immunomodulatory 
activity23. Immunomodulators are those intrinsic or 
extrinsic substances that regulate or alter the scope, 
type, duration, or competency of the immune system24. 
Various Rasayana drugs having immunomodulatory 
action have been studied and are used to deal  
with a vast array of clinical conditions like viral 





Understanding the patho-physiology of COVID-19 as per 
Ayurveda principles 
According to Ayurveda, all the diseases cannot  
be named with standard nomenclature. Instead of 
trying to name the disease entity, the physician  
needs to examine the three important factors,  
viz. Samutthana-vishesha (Specific causative factors 
of the disease), Adhishthana-vishesha (Site of 
manifestation of the disease), and Vikara-prakriti 
(Pathophysiology of the disease), for designing a 
rational line of management25. 
Samutthana-Vishesha 
COVID-19 pandemic can be understood based on 
the Ayurveda principles of Aupasargika Roga12 and 
Janapadodhvamsa15. Further, the disease can be 
grouped under Bhutabhishangaja Agantuja Jvara 
(Fever caused by the micro-organisms). Agantuja 
factor (Bhutabhishanga) causes prodromal symptoms 
initially and eventually leads to the vitiation of Nija 
(Host) factors i.e., Tridosha in the due course of the 
disease, which in turn manifests the clinical features 
of the disease19,26,27. 
 
Adhishthana-Vishesha and Vikara-Prakriti 
A recent systematic review and meta-analysis show 
that the fever (87.3%), cough (58.1%), dyspnea 
(38.3%), muscle soreness or fatigue (35.5%), and 
chest distress (31.2%) were the most common clinical 
manifestations. Among the patients, the incident for 
intensive care requirement, acute respiratory distress 
syndrome, and multiple organ dysfunction syndrome 
was 29.3%, 28.8%, and 8.5%, respectively with a 
6.8% case fatality rate28. 
On the basis of symptomatology, its clinical 
appearance can be depicted in Shat-kriyakala (Six 
levels of pathogenesis) described in Ayurveda29. The 
progression and clinical manifestations of COVID-19 
across six stages of pathogenesis may vary with 
reference to severity or time-lapse depending upon the 
epidemiological triad of the Host-Agent-Environment. 
This variation can rightly be explained with  
Ayurvedic concept of ‘Vikara-Vighata-Bhava-Abhava’ 
(Disease presentation) leading to Vikara-Ajananam 
(Asymptomatic condition), Chirena-Jananam 
(Insidious onset or longer incubation period) or 
Shighra-Jananam (Acute onset or shorter incubation 
period), Anuvikara-Jananam (Mild stage), 
Asarvalinga-Vikara-Jananam (Moderate stage) and 
Sarvalinga-Vikara-Jananam (Full-blown disease 
manifestation)30. Among the triad (Host-Agent-
Environment), the ability of the host to resist the 
disease manifestation (Vyadhi-Kshamatva) is crucial 
and the extent of encompassment of factors related to 
Apathya, Dosha & Sharira will eventually decide the 
severity of disease manifestation & its prognosis20. 
 
Sanchaya (Stage of accumulation) and Prakopa (Stage of 
provocation) 
These are the initial stages of pathogenesis where 
only the symptoms of Dosha-vriddhi (Quantitative 
increase in Dosha) will be present, mostly subjective 
to the patient, hence mostly ignored. However, in a 




subset of people, due to their habitual non-conducive 
diet and regimens, the Alpa Prakupita (Mildly 
provoked) Dosha are already in Leena Avastha 
(Quiescent state) at the level of Shakha or Dhatu 
(Different structural components of the body), even 
prior to the infection. After contact with the pathogen, 
it leads to an accelerated progression to the next 
stage31. This subclinical stage can be identified by the 
presence of the symptoms like heaviness of the body, 
lethargy etc32. in a quarantined person and should be 
managed promptly to arrest the progression of the 
disease or to reduce its severity. 
 
Prasara (Stage of migration) 
It is also a pre-clinical stage but with moderate 
symptoms e.g. Anorexia, languor, etc. caused by the 
migration of vitiated Dosha33. Anecdotal evidence of 
anosmia and ageusia with no other symptoms of 
COVID-19, a short period before the patients 
ultimately tested positive, draws attention to this 
stage34. Aprasannendriyatvam (disability of the sense 
organs to perceive) is also a deductive tool to 
understand Dosha vitiation35. 
 
Sthana-samshraya (Stage of localization) 
This is the first clinical phase where the vitiated 
Dosha get confined to a site or system causing the 
onset of prodromal symptoms36. In COVID-19, the 
vitiated Dosha afflict Koshtha (Viscera), Rasavaha 
Srotas (Channels carrying various types of body 
fluids), and Pranavaha Srotas (Channels of the 
respiratory system) causing the onset of prodromal 
symptoms of fever and cough e.g. Lethargy, 
heaviness of the body, anorexia, distaste in mouth, 
myalgia, throat irritation with prickly sensation 
etc37,38. 
If any Sroto-vaigunya (Deformity in body 
channels) is already present there e.g. Respiratory 
disorders, Cardio-vascular disorders, etc., it makes the 
COVID-19 manifest in a more complex pattern during 
upcoming stages. 
 
Vyakti (Stage of manifestation) 
This stage of full-blown disease manifests with the 
features of Vata-Kapha predominant Sannipata Jvara 
(Fever with a conglomeration of Tridosha due to 
Bhutabhishanga)26,27 and Vata predominant Kasa 
(Dry cough). Here, the predominance of Vata and 
Kapha in fever is inferred by the presence of 
symptoms like cough & dyspnea39. While the 
predominance of Vata in Kasa is inferred by the 
presence of symptoms like dry coughing (Shushka 
Kasa) caused by Pratiloma Gati (Upward movement) 
and Ruksha (Dry) property of Vata Dosha40. 
Here, the site of localization of migrating Dosha 
i.e., Pranavaha Srotas (Channels of the respiratory 
system) and site of origin of fever i.e. Amashaya (Part 
of Gastro-intestinal tract dealing with undigested 
food) are directly related with the physiological sites 
of Kapha Dosha41. 
 
Bheda (Stage of complications) 
In this stage, the Vata-Kapha predominant fever 
progresses into Sama-Sannipata Jvara (Fever with an 
equal conglomeration of Tridosha) with all the signs 
and symptoms, ultimately ending in the development 
of Upadrava (Complications) i.e., Shvasa Roga 
(Severe pneumonia and ARDS)40-42. As per Ayurveda, 
the complication arises due to the undergoing 
Dhatupaka (Excessive inflammation in different 
structural components of the body as a result of the 
overwhelmed immune response)43. This may further 
lead to multi-organ failure and shock which require 
life support measures and has very poor prognosis or 
the person may survive with some sequel finally 
leading to death. 
The factors e,g. Samsrishta-yoni (Involvement  
of other tissues or organs), Viruddha-upakrama  
(Need of administration of multiple therapies  
which are contradictory in nature), Gambhira-
anugatam (Complex pathogenesis), Chira-sthitatvam 
(Chronicity), Pranayatana-samuttham (Involving 
vital organs) and Marma-upagathi (Causing damage 
to vital organs) can also influence the severity of 
symptoms and duration of their onset20. 
 
Integrative approach – The key 
During this ongoing COVID-19 pandemic, 
although numerous efforts are being made by 
conventional medicine to find effective therapy, no 
significant outcome has been achieved until now. 
Therefore, in this global crisis, where the countries 
even with the efficient healthcare systems are unable 
to control its spread, it’s crucial to explore the best 
possible options available and integration of 
traditional & complementary systems of medicine 
with conventional medicine appears to be the way 
forward. 
WHO advocates that Traditional and 
Complementary Medicine (T & CM) can make a 
significant contribution to the goal of universal health 
coverage by being included in the provision of 




essential healthcare services. According to the latest 
report of WHO on T & CM, the uniformly high use of 
T & CM across all regions reinforces the integration 
of T & CM products, practices, and practitioners into 
health systems. It has also mentioned that countries 
aiming to integrate the best of T & CM and 
conventional medicine would do well to look at areas 
where both converge to help tackle the unique health 
challenges of the 21st century and emphasized the 
significance of T & CM that balances curative 
services with preventive care44. 
Also, the key principle of the National Health 
Policy of India-2017 is to promote the pluralism 
based approach of integrative healthcare. It advocates 
the co-location and integration of AYUSH systems at 
various levels to meet the national health goals and 
objectives. It also highlights the promotion of healthy 
living and preventive strategies of AYUSH systems in 
the community45. The AYUSH manpower and 
therapeutics have already been implemented at 
different levels throughout the country in various 
states46. National Institution for Transforming  
India (NITI) Aayog, a policy think tank of the 
Government of India, also focuses on integrative 
practices, prevention & lifestyle interventions, and 
dissemination of traditional cultural practices47. 
Moreover, the Government of China, in it’s 
campaign to contain and eradicate SARS-CoV-2, has 
successfully integrated Traditional Chinese medicine 
(TCM) in the patients of COVID-1948. In this regard, 
guidelines of diagnosis and treatment for COVID-19 
using TCM have been published wherein different 
TCM protocols for different stages of COVID-19 are 
detailed and for critical patients, TCM has been 
recommended along with western medicine11. Further, 
the National Health Commission of China had 
approved a TCM drug namely ‘Qing-Fei-Pai-Du-
Tang’ (QPT) for a clinical trial on COVID-19 cases 
and subsequently recommended it across the country 
after obtaining clinically valid data with an overall 
effective rate of ≥ 90. Accordingly, a total of 701 
COVID-19 cases were treated with it, out of which, 
18.5% cases cured completely whereas 7.27%, 38.2% 
and 30.2% cases got symptomatic relief, symptomatic 
improvement, and clinically stabilized respectively. 
After this significant outcome, they decided to use 
TCM in combination with conventional medicine for 
the treatment of COVID-19 and also reported that a 
total of 60,107 confirmed COVID-19 cases have been 
treated using TCM8. 
Among 382 registered clinical trials (379 in China) 
on the WHO’s International Clinical Trials Registry 
Platform aiming to evaluate the efficacy and safety of 
treatment and prevention of COVID-19, 98 trials are 
related to the TCM (includes 48 named TCMs; 27 
unspecified methods; 18 combinations with 
unspecified western therapies; and 5 others, e.g. 
acupuncture)49. 
In India where seasonal and non-specific viral-
illnesses are quite common, Ayurveda has been used 
for centuries for dealing with such conditions. 
Tremendous research work has also been carried out 
to evaluate the antiviral and immune-modulating 
properties of various Ayurvedic herbs. In recent 
developments related to the management of COVID-
19, various Indian states i.e. Kerala, Haryana & Goa 
have implemented an integrative approach using 
different Ayurveda protocols for prevention and 
treatment of COVID-19 in different types of cases 
viz. quarantined and confirmed mild cases. 
Ministry of AYUSH (MoA), Government of India 
has also issued the various guidelines for the 
prevention of COVID-19 incorporating immunity-
boosting measures which are based on Ayurvedic 
principles and are supported by researches50,51. MoA 
has asked the stakeholders to manufacture ‘Ayush 
Kvatha’ and has taken steps to expedite the process of 
manufacturing of Ayurvedic immunity-boosting 
products52,53. It is supporting the research projects 
evaluating AYUSH interventions in prophylaxis and 
management of COVID-1954. In recent developments, 
MoA has launched clinical research studies using 
Ayurvedic interventions as an add-on to standard care 
to the COVID-19 situation. A population-based study, 
through the ‘AYUSH Sanjivani’ mobile app, has also 
launched to assess the acceptance and usage of 
AYUSH advisories and other measures among the 
population and to understand its role in the prevention 
of COVID-19(ref. 55). In addition, scientific efforts to 
develop a pragmatic action plan to address COVID-19 
through Ayurveda are also being done56. 
Broadly the Ayurvedic strategy of management can 
be divided into preventive & curative aspects as per 
the stage and severity of the illness based on the 
Ayurvedic principles of management of 
Janapadodhvamsa, Balagraha, Jvara, Pratishyaya, 
Kasa, and Swasa. 
 
Pre-exposure prophylaxis 
Along with conventional guidelines designed for 
prevention of COVID-19, some additional Ayurvedic 




guidelines are proposed which can be followed by the 
asymptomatic, healthy, and non-risky groups. 
Pratimarsha Nasya57 (Nasal application by 
instilling two drops in each nostril once in the morning) 
of Anu Taila58 may be taken to strengthen the first line 
of defense i.e., Nasal mucosa, hairs, and cilia, etc. 
Epidemics-specific measures of Ayurveda59 e.g. 
Shodhana (Bio-purification therapy) to subside 
previously accumulated Dosha (Previously disturbed 
homeostasis), Rasayana (Rejuvenation therapy) to 
obtain an optimal level of different structural 
components of the body), Sadvritta (Nobel moral 
conducts)61 and Achara Rasayana (Good rejuvenating 
conducts)62 to strengthen the mental attributes may be 
adopted. Sadyo-Snehana (Immediate oleation of the 
body) with 50 to 100 mL of plain Ghee along with 
Yavagu (Rice-gruel) in the night meal or when you feel 
hungry followed by Sadyo-Virechana (Immediate 
purgation) with 10 to 15 grams of Avipatti Yoga60 with 
warm water, empty stomach in the early morning may 
be used for Shodhana. 10 to 20 g of Chyavanprasha58 
with warm milk on empty stomach in the morning may 
serve the purpose of using Rasayana. De-addiction, 
observing charity, Yogasana (Postures) like 
Suryanamskara (Sun salutation), Pranayama 
(controlled breathing exercises), Emotional equipoise, 
etc. are the measures which can be adopted under 
Sadvritta and Achara Rasayana. Ayurvedic measures 
of Graha Roga (Infectious diseases)63 i.e., Dhupana 
(Fumigation) with Krimighna and Rakshoghna (Herbal 
anti-microbial) drugs e.g. Onion and garlic tunics, 
mustard seeds, Neem leaves and Ghee, etc. may be 
used in order to sanitize the surrounding environment. 
Ayurvedic Ahara-Vidhi (Dietary conducts)64 may 
be adopted to get optimal dietary benefits e.g. Dhatu-
Poshana (Overall nutrition) and Bala-Vriddhi 
(Immunity enhancement) etc. Taking Laghu Ahara 
(Easily digestible food), Matravat Ahara (Food in 
appropriate quantity), Kalanusara Ahara (Food in 
accordance with age, season, etc.), Jirne Ashniyat 
(Taking meal only after proper digestion of previously 
taken meal) and Susamskarita Ahara (Diet with 
desired properties e.g. adding ginger, Ghee, garlic, 
black-pepper & turmeric, etc. while cooking food to 
increase metabolism) is the chief dietary conducts 
should be followed. Intake of Ushna Jala65 (Boiled 
warm water) as and when required may also be 
beneficial in this stage. 
The interventions in these groups are planned with 
the assumption that contact with the virus has not 
occurred. Here the target is to prepare the host to 




Some additional guidelines proposed here may be 
followed along with conventional guidelines designed 
for prevention of COVID-19 and specific measures 
mentioned in pre-exposure prophylaxis by the high 
risk-groups e.g. quarantined population and healthcare 
workers etc. 
Intake of Shadangapaniya58 (lukewarm medicated 
water prepared by adding 30 g of the powder of 
Shadangapaniya into two liters of water and boiling it 
to half) throughout the day may be beneficial. 
Clinically, the immune responses induced by 
SARS-CoV-2 infection are two-phased. During the 
incubation and non-severe stages, a specific adaptive 
immune response helps in the elimination of the virus 
that in-turn helps to prevent disease progression to 
severe stages. The successful elimination of the 
infection relies on the general health status and 
appropriate genetic background of the infected 
individual eliciting specific antiviral immunity56. 
Therefore, the use of immunomodulatory Rasayana 
drugs at this stage will be certainly fruitful. However 
when the patient enters the severe stage, when a 
strong damaging inflammatory response occurs, 
especially in the lungs, the immunostimulatory 
approach will be of no use. Hence the use of some 
most widely practiced and researched Rasayana  
drugs with known immunomodulatory activities  
e.g. Guduchi (Tinospora cordifolia)67,68, Ardraka 
(Zingiber officinalis)69,70, Amalaki (Emblica officinalis 
or Phyllanthus emblica)71,72, Haridra (Curcuma 
longa)73,74, Tulasi (Ocimum sanctum)75,76, 
Ashwagandha (Withania somnifera)77,78 & 
Madhuyashti (Glycyrrhiza glabra)79,80, etc. may be of 
utmost importance in high-risk groups and 
quarantined people as a prophylactic measure. 
The interventions in these groups are planned with 
the assumption that the contact with the virus has 
already occurred but the person is asymptomatic and 
suspected to contract the infection. Here the target is 
to improve the host response to reduce virulence and 
arrest the further progression of the pathogenesis. 
 
Management of COVID-19 cases 
If any clinical manifestation of COVID-19 appears 
and the individual is found confirmed with COVID-
19, it can be managed with conventional treatment of 




COVID-19 along with below proposed Ayurvedic 
guidelines. The interventions are planned according to 
the clinical manifestations and disease progression as 
per Ayurveda staging system and on the management 
principles of Jvara (Infective fevers), Pratishyaya 
(Coryza), Kasa (Cough) and Shvasa (Dyspnea) 
described in standard Ayurveda classics. 
 
Stage-I: Anuvikara-Jananam (Mild clinical cases) 
In cases with early symptoms of COVID-19 i.e., 
Dry cough, body-ache and fever, etc. corresponding 
to Vata-Kapha predominant fever, some additional 
strategies can be used along with prophylactic 
measures described earlier.  
Herbal drugs having Aama-Pachana (Eliminating 
intermediate inflammatory metabolites by improving 
sluggish metabolism) property e.g. Amrittottara 
Kvatha58 and Jvarahara (Fever pacifying) property 
e.g. Samshamani Vati81 and Sudarshana Churna58 etc. 
may be administered at this stage. Herbal drugs with 
known antiviral properties e.g. Kalmegha 
(Andrographis paniculata)82,83, Haridra (Curcuma 
longa)83,84, Ashwagandha (Withania somnifera)85,86, 
Guduchi (Tinospora cordifolia)86,87, Tulasi (Ocimum 
sanctum)87,84, Madhuyashti (Glycyrrhiza glabra)84,88, 
Ardraka (Zingiber officinalis)89,90 & Haritaki 
(Terminalia chebula)91,92, etc. may also be 
administered here. 
 
Stage-II: Asarvalinga-Vikara-Jananam (Moderate clinical 
cases) 
Herbal drugs having Shvasa-Kasahara (Dyspnoea 
and cough pacifying) properties may be administered 
along with Stage-I measures in the cases of COVID-
19 having respiratory symptoms i.e., Shortness of 
breath etc. Some widely practiced Shvasa-Kasahara 
formulations are Sitopaladi Churna58, Talisadi 
Churna58, Gojihvadi Kvatha80, Agastya Haritaki 
Rasayana58 & Vyaghri Haritaki Rasayana81, etc. 
 
Stage-III: Sarvalinga-Vikara-Jananam (Severe cases) along 
with Upadrava (Complications) 
Along with the measures described in Stage-II, few 
additional measures can be adopted for COVID-19 
cases developing severe pneumonia & ARDS, 
corresponding to Sama-Sannipata-Jvara with 
underlying Dhatupaka (Fever with organ damage).  
Herbal formulations having Sannipata Jvara 
pacifying property e.g. Shatyadi Kvatha93 may be 
administered in this stage. The herbo-mineralo-
metallic formulations having the cumulative 
properties of pacifying Jvara, Shvasa, Kasa & 
Pratishyaya e.g. Mahalakshmivilasa Rasa58, 
Shvasakasachintamani Rasa81 & Shringarabha 
Rasa81, etc. may also be administered. 
Safety & efficacy of said formulations can be 
inferred from their high use in general practice & also 
by relatively high production by leading Ayurveda 
Pharmaceutical establishments in accordance with 
Ayurvedic pharmacopeia & formulary of India. 
Appropriate modifications in treatment can be made 
in children, old persons & those with comorbidities. 
However, the Ayurveda is a personalized medicine 
system, so one can choose the dosage, number & 
combination of formulations described above 
rationally. It is also recommended to use all 
preventive measures as described in pre-exposure 
prophylaxis during follow-up to prevent a recurrence. 
 
Conclusion 
In the case of COVID-19, it may be hypothesized 
that initial Bhutabhishanga (Infection) leads to the 
vitiation of Tridosha which in-turn manifests as Vata-
Kapha predominant Sannipata Jvara with prominent 
features of Jvara (Fever), Kasa (Cough) & Shvasa 
(Dyspnea). The vitiation of Dosha manifests through 
Sanchaya, Prakopa, Prasara & Sthana-Samshraya 
stages causing prodromal symptoms. Further vitiation 
of Tridosha, leads to the progression of the disease to 
Vyakti & Bheda stages where advanced 
manifestations of COVID-19 i.e. Severe Pneumonia, 
ARDS & septic shock are manifested. 
The manifestation of the disease from carrier state 
to mild symptoms to full-blown disease with fatal 
outcome depends upon Vyadhikshamatva & Bala 
(Immunity) and status of the Srotas (Body systems) of 
the host. Hence, the individuals with impaired 
Vyadhikshamatva & Bala i.e. old age, etc. & with pre-
existing Sroto-Vaigunya (Co-morbidities) have more 
severe & fatal outcomes. 
Preventive & management protocols of Ayurveda 
for COVID-19 may be planned on the principles of 
management described in Janapadodhvamsa 
(Epidemics), Graha-roga (Infectious diseases), Jvara 
(Infective fevers), Pratishyaya (Coryza), Kasa 
(Cough) & Shvasa (Dyspnea), and information 
available through contemporary published literature 
related to immunomodulatory & antiviral properties 
of selected Ayurvedic herbs. The same can also be 
taken up for further research towards the prevention 
and management of COVID-19. 
In this crisis of global pandemic, it’s high time for 
the policy-makers and healthcare stakeholders of the 




country to acknowledge the treasure of scientific 
traditional wisdom and to give due recognition by 
incorporating Ayurveda into the action strategy as a 
full-fledged healthcare system to fight against 
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